Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sage Therapeutic Com
(NQ:
SAGE
)
6.860
+0.050 (+0.73%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sage Therapeutic Com
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Outset Medical, Starbucks, Endava, and Sage and Encourages Investors to Contact the Firm
October 15, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
October 15, 2024
From
Sage Therapeutics, Inc.
Via
Business Wire
SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Sage Therapeutics, Inc. Investors of Upcoming Deadline
October 14, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
The Analyst Verdict: Sage Therapeutics In The Eyes Of 13 Experts
October 04, 2024
Via
Benzinga
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage Therapeutics
October 11, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Outset Medical, Starbucks, Endava, and Sage and Encourages Investors to Contact the Firm
October 09, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Netflix To $650? Here Are 10 Top Analyst Forecasts For Wednesday
October 09, 2024
Via
Benzinga
After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study
October 08, 2024
Sage Therapeutics' dalzanemdor failed to show significant results in Phase 2 Alzheimer's study. The company discontinues Alzheimer's development but expects Huntington's data soon. Stock drops 10.7%.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 08, 2024
Via
Benzinga
Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease
October 08, 2024
From
Sage Therapeutics, Inc.
Via
Business Wire
SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Sage Therapeutics, Inc. Investors of Upcoming Deadline
October 07, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
ROSEN, A RANKED AND LEADING FIRM, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGE
October 06, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Outset Medical, Starbucks, Endava, and Sage and Encourages Investors to Contact the Firm
October 05, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
SAGE REMINDER – Robbins LLP Urges SAGE Investors to Obtain Legal Counsel in Light of the Pending Lead Plaintiff Deadline
October 04, 2024
From
Robbins LLP
Via
GlobeNewswire
Rivian Automotive Cuts Production Outlook, Joins EVgo And Other Big Stocks Moving Lower In Friday's Pre-Market Session
October 04, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
October 04, 2024
Via
Benzinga
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage Therapeutics
October 02, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Outset Medical, Starbucks, Endava, and Sage and Encourages Investors to Contact the Firm
October 01, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Sage Therapeutics, Inc. Investors of Upcoming Deadline
September 30, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Methode Electronics, Starbucks, Endava, and Sage and Encourages Investors to Contact the Firm
September 26, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGE
September 26, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate
September 26, 2024
Sage Therapeutics announced Biogen's decision to terminate their collaboration on SAGE-324 following negative results from a Phase 2 study, with Sage resuming full ownership of the asset by February...
Via
Benzinga
Sage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program
September 26, 2024
From
Sage Therapeutics, Inc.
Via
Business Wire
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage Therapeutics
September 25, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Sage Therapeutics, Inc. Investors of Upcoming Deadline
September 23, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sage, Outset Medical, Allarity, and Super Micro and Encourages Investors to Contact the Firm
September 22, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage Therapeutics
September 19, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sage, Outset Medical, and Super Micro and Encourages Investors to Contact the Firm
September 18, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Sage Therapeutics, Inc. (SAGE)
September 18, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
SAGE CLASS ACTION: Sage Therapeutics, Inc. Stockholders Should Contact Robbins LLP for Information About the Securities Class Action Lawsuit
September 17, 2024
From
Robbins LLP
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.